Citations

Clear

6273 citation(s) found for "To, Andrew".

LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner
Ohkawara, Bisei , Cabrera‐Serrano, Macarena , Nakata, Tomohiko, Milone, Margherita , Asai, Nobuyuki, Ito, Kenyu , Ito, Yasutomo, Engel, Andrew G. , Ohno, Kinji , Ito, Mikako , Masuda, Akio

Mayo Clinic

Human Molecular Genetics | November 15, 2013 | Volume: 23 | Issue: 7 | Pages: 1856-1868

10.1093/hmg/ddt578 | PMID 24234652 Get It

Abstract Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Using Sanger and exome sequencing in a CMS patient, we identified two heteroallelic mutations, p.Glu1233Lys and p.Arg1277His, in LRP4 coding for the postsynaptic low-density lipoprotein receptor-related protein 4. LRP4, expressed on the surface of the postsynaptic membrane of the neuromuscular junction, is a receptor for neurally secreted agrin, and LRP4 bound by agrin activates MuSK. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR on the postsynaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the neuromuscular junction. LRP4 also functions as an inhibitor of Wnt/beta-catenin signaling. The identified mutations in LRP4 are located at the edge of its 3rd beta-propeller domain and decrease binding affinity of LRP4 for both MuSK and agrin. Mutations in the LRP4 3rd beta-propeller domain were previously reported to impair Wnt signaling and cause bone diseases including Cenani–Lenz syndactyly syndrome and sclerosteosis-2. By analyzing naturally occurring and artificially introduced mutations in the LRP4 3rd beta-propeller domain, we show that the edge of the domain regulates the MuSK signaling whereas its central cavity governs Wnt signaling. We conclude that LRP4 is a new CMS disease gene and that the 3rd beta propeller domain of LRP4 mediates the two signaling pathways in a position-specific manner.
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease
Benzinger, Tammie L.S. , Blazey, Tyler , Xiong, Chengjie , Raichle, Marcus E. , Ances, Beau M. , Bateman, Randall J. , Cairns, Nigel J., Fagan, Anne M. , Goate, Alison , Marcus, Daniel S. , Aisen, Paul, Christensen, Jon, Ercole, Lindsay, Hornbeck, Russ C. , Farrar, Angela, Aldea, Patricia, Jasielec, Mateusz S., Owen, Christopher J. , Xie, Xianyun, Mayeux, Richard , Klunk, William E. , Mathis, Chester A. , Ringman, John M. , Thompson, Paul M. , Saykin, Andrew J. , Johnson, Keith A. , Salloway, Stephen , Correia, Stephen , Schofield, Peter R. , Masters, Colin L. , Villemagne, Victor L. , Martins, Ralph N. , Ourselin, Sébastien , Rossor, Martin N. , Fox, Nick C. , Cash, David M. , Weiner, Michael W. , Buckles, Virginia, Moulder, Krista L., Morris, John C. , Jack, Clifford R. , Koeppe, Robert A. , Su, Yi , Xiong, Chengjie , Snyder, Abraham Z. , Brickman, Adam M. , McDade, Eric , Ghetti, Bernardino , Sperling, Reisa Anne , Rowe, Christopher Cleon , Holtzman, David M. , Saykin, Andrew J , Schofield, Peter R , Thompson, Paul M , Bateman, Randall J , Masters, Colin L , Benzinger, Tammie L S , Ances, Beau M , Fox, Nick C , Morris, John C , Cash, David M , Goate, Alison M

Mayo Clinic

Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available

10.1073/pnas.1317918110 | PMID 24194552 Get It

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.
Use of Antidepressant Medication in the United States During Pregnancy, 2002–2010
Meunier, Matthew R. , Bennett, Ian M. , Coco, Andrew

Mayo Clinic

Psychiatric Services | November 1, 2013 | Volume: 64 | Issue: 11 | Pages: 1157-1160

10.1176/appi.ps.201200455 | PMID 24185537 Get It

Pneumatic Compression for Embolic Protection During Upper Extremity Endovascular Intervention
Cassar, Andrew, Barsness, Gregory W. , Wysokiński, Waldemar E. , Gifford, Shaun M., Bower, Thomas C., Edwards, William D. , Gulati, Rajiv , Wysokinski, Waldemar

Mayo Clinic

Vascular and Endovascular Surgery | November 1, 2013 | Volume: 48 | Issue: 1 | Pages: 70-73

10.1177/1538574413510622 | PMID 24178727 Get It

Embolic protection devices are occasionally employed during endovascular interventions to prevent complications caused by embolic debris. However, these devices have imperfect efficacy, confer risk of endovascular trauma, and are expensive. We report a patient with giant cell arteritis and symptomatic axillary artery stenosis, with a perceived elevated risk of distal embolization during endovascular intervention. We describe a straightforward embolic protection technique of brachial pressure cuff inflation during endovascular intervention and aspiration of displaced thrombotic material from the static column of blood. This novel, effective, and cost-free technique could also be employed in other vascular beds during endovascular intervention.
Iodamoeba butschlii in an anal pap test confirmed by iodine stain
Pritt, Bobbi S. , Schreiner, Andrew M., Schuetz, Audrey N. , Pritt, Bobbi S

Mayo Clinic

Diagnostic Cytopathology | October 25, 2013 | Volume: 42 | Issue: 9 | Pages: 775-777

10.1002/dc.23042 | PMID 24167099 Get It

We report the finding of Iodamoeba butschlii amebic cysts on a liquid‐based anal Pap smear from an HIV‐positive male. Iodine staining of the smear confirmed the diagnosis. It is important to distinguish I. butschlii from pathogenic ameobae and other organisms seen on anal Pap smears. Diagn. Cytopathol 2014;42:775–777. © 2013 Wiley Periodicals, Inc.
Sex-Related Differences in Fractional Flow Reserve–Guided Treatment
Li, Jing , Rihal, Charanjit S. , Matsuo, Yoshiki , Elrashidi, Muhamad Y. , Flammer, Andreas J. , Lee, Moo-Sik, Cassar, Andrew, Lennon, Ryan J. , Herrmann, Joerg, Bell, Malcolm R. , Holmes, David R. , Bresnahan, John F., Hua, Qi , Lerman, Lilach O. , Rihal, Charanjit S. , Herrmann, Joerg, Lerman, Amir

Mayo Clinic

Circulation: Cardiovascular Interventions | October 23, 2013 | Volume: 6 | Issue: 6 | Pages: 662-670

10.1161/circinterventions.113.000762 | PMID 24149976 Get It

Background— Sex-specific differences affect the evaluation, treatment, and prognosis of coronary artery disease. We tested the hypothesis that long-term outcomes of fractional flow reserve (FFR)–guided percutaneous coronary intervention (PCI) are different between women and men. Methods and Results— Consecutive 1090 patients, referred for PCI and undergoing FFR measurements at the Mayo Clinic between October 2002 and December 2009, were included in this registry study. Clinical events were compared between the sexes during a median follow-up of 50.9 months. Of all patients, women had higher FFR adjusted by visual coronary stenosis than men ( P =0.03). The Kaplan–Meier percent of major adverse cardiac events at 5 years was 35% in women and 38% in men ( P =0.54). Interestingly, in patients undergoing PCI with an FFR <0.75, the incidence of death or myocardial infarction was significantly higher in women than in men (hazard ratio, 2.16; 95% confidence interval, 1.04–4.51; P =0.04). Moreover, compared with patients with FFR >0.80, deferral of PCI for those with FFR between 0.75 and 0.80 was associated with an increased rate of major adverse cardiac events, particularly death or myocardial infarction in women (hazard ratio, 3.25; 95% confidence interval, 1.56–6.74; P =0.002) and revascularization in men (hazard ratio, 2.66; 95% confidence interval, 1.66–4.54; P <0.001). Conclusions— Long-term outcome differs between women and men undergoing FFR-guided PCI. Our data suggest that the sex-based treatment strategy is necessary to further optimize prognosis of patients with coronary artery disease.
Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation
Harrison, Andrew M. , Thalji, Nassir M , Greenberg, Alexandra J. , Tapia, Carmen J., Windebank, Anthony J. , Harrison, Andrew Marc

Mayo Clinic

Clinical and Translational Science | October 12, 2013 | Volume: 7 | Issue: 1 | Pages: 82-86

10.1111/cts.12111 | PMID 24528902 Get It

AbstractTranslational stories range from straightforward to complex. In this commentary, the story of the rapid and successful translation of rituximab therapy for the treatment of non‐Hodgkin's lymphoma (NHL) is examined. Development of this monoclonal antibody therapy began in the late 1980s. In 1994, rituximab received its first approval for the treatment of NHL by the United States Food and Drug Administration (FDA). Rituximab has since been approved for additional indications and has transformed medical practice. However, the social and political implications of these rapid successes are only beginning to become clear. In this commentary, key events in the rapid translation of rituximab from the bench to bedside are highlighted and placed into this historical framework. To accomplish this, the story of rituximab is divided into the following six topics, which we believe to be widely applicable to case studies of translation: (1) underlying disease, (2) key basic science, (3) key clinical studies in translation, (4) FDA approval process, (5) changes to medical practice, and (6) the social and political influences on translation.
O4–03–03: Disrupted functional connectivity in autosomal dominant Alzheimer's disease demonstrates network specificity and precedes brain volume loss: Findings from the Dominantly Inherited Alzheimer Network
Chhatwal, Jasmeer P. , Johnson, Keith A. , Sullivan, Caroline, Salloway, Stephen , Ringman, John M. , Marcus, Daniel S. , Correia, Stephen , Rowe, Christopher C., Mayeux, Richard , Xiong, Chengjie , Buckles, Virginia, Schultz, Aaron P. , Benzinger, Tammie L.S. , Jack, Clifford R. , Ances, Beau M. , Koeppe, Robert A. , Thompson, Paul M. , Saykin, Andrew J. , Schofield, Peter R. , Fox, Nick C. , Brickman, Adam M. , McDade, Eric , Bateman, Randall J. , Goate, Alison , Xiong, Chengjie , Morris, John C. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2013.04.348 Get It

IC‐P‐082: Disrupted functional connectivity in autosomal dominant Alzheimer's disease demonstrates network specificity and precedes brain volume loss: Findings from DIAN
Chhatwal, Jasmeer P. , Johnson, Keith A. , Sullivan, Caroline, Salloway, Stephen , Ringman, John M. , Marcus, Daniel S. , Correia, Stephen , Rowe, Christopher C., Mayeux, Richard , Xiong, Chengjie , Buckles, Virginia, Schultz, Aaron P. , Benzinger, Tammie L.S. , Jack, Clifford R. , Ances, Beau M. , Koeppe, Robert A. , Thompson, Paul M. , Saykin, Andrew J. , Schofield, Peter R. , Fox, Nick C. , Brickman, Adam M. , McDade, Eric , Bateman, Randall J. , Goate, Alison , Xiong, Chengjie , Morris, John C. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2013.05.079 Get It